{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T14:30:46Z","timestamp":1719844246562},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s13181-010-0035-4","type":"journal-article","created":{"date-parts":[[2010,3,5]],"date-time":"2010-03-05T11:17:30Z","timestamp":1267787850000},"page":"41-43","source":"Crossref","is-referenced-by-count":6,"title":["Respiratory Failure Following Isolated Ziprasidone Ingestion in a Toddler"],"prefix":"10.1007","volume":"6","author":[{"given":"Chip","family":"Gresham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"Ruha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,6]]},"reference":[{"issue":"6","key":"35_CR1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/cap.2006.0126","volume":"17","author":"RP Malone","year":"2007","unstructured":"Malone RP, Delaney MA, Hyman SB et al (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17(6):779\u2013790","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"35_CR2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1399-5618.2007.00450.x","volume":"9","author":"J Biederman","year":"2007","unstructured":"Biederman J, Mick E, Spencer T et al (2007) A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 9(8):888\u2013894","journal-title":"Bipolar Disord"},{"issue":"4","key":"35_CR3","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ajem.2004.09.033","volume":"23","author":"F LoVecchio","year":"2004","unstructured":"LoVecchio F, Watts D, Eckholdt P (2004) Three-year experience with ziprasidone exposures [letter]. Am J Emerg Med 23(4):586\u2013587","journal-title":"Am J Emerg Med"},{"key":"35_CR4","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.emc.2007.02.003","volume":"25","author":"TH Reilly","year":"2007","unstructured":"Reilly TH, Kirk MA (2007) Atypical antipsychotics and newer antidepressants. Emerg Med Clin North Am 25:477\u2013497","journal-title":"Emerg Med Clin North Am"},{"issue":"5","key":"35_CR5","first-page":"624","volume":"40","author":"G Lackey","year":"2002","unstructured":"Lackey G, Alsop J, Albertson T (2002) A one year review of pediatric ziprasidone ingestions [abstract]. J Toxicol Clin Toxicol 40(5):624","journal-title":"J Toxicol Clin Toxicol"},{"issue":"2","key":"35_CR6","first-page":"81","volume":"45","author":"SM Bryant","year":"2003","unstructured":"Bryant SM, Zilberstein J, Cumpston KL et al (2003) A case series of ziprasidone overdoses. Vet Hum Toxicol 45(2):81\u201382","journal-title":"Vet Hum Toxicol"},{"issue":"2","key":"35_CR7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1081\/CLT-120019121","volume":"41","author":"AK Biswas","year":"2003","unstructured":"Biswas AK, Zabrocki LA, Mayes KL et al (2003) Cardiotoxicity associated with intentional ziprasidone and buproprion overdose. J Toxicol Clin Toxicol 41(2):101\u2013104","journal-title":"J Toxicol Clin Toxicol"},{"issue":"6","key":"35_CR8","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1089\/cap.2005.15.970","volume":"15","author":"SX Anita","year":"2005","unstructured":"Anita SX, Sholevar EH, Baron DA (2005) Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 15(6):970\u2013985","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"35_CR9","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1176\/appi.ajp.160.7.1355-a","volume":"160","author":"J Teich","year":"2003","unstructured":"Teich J (2003) Side effects of ziprasidone. Am J Psychiatry 160:1355\u20131356","journal-title":"Am J Psychiatry"},{"key":"35_CR10","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/15563650701639006","volume":"45","author":"W Klein-Schwartz","year":"2007","unstructured":"Klein-Schwartz W, Lofton AL, Benson BE et al (2007) Prospective observational multi-poison center study of ziprasidone exposures. J Toxicol Clin Toxicol 45:782\u2013786","journal-title":"J Toxicol Clin Toxicol"},{"issue":"6","key":"35_CR11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","volume":"45","author":"FR Sallee","year":"2006","unstructured":"Sallee FR, Miceli JJ, Tensfeldt T et al (2006) Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psych 45(6):720\u2013728","journal-title":"J Am Acad Child Adolesc Psych"},{"issue":"11","key":"35_CR12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00002018-200528110-00004","volume":"28","author":"GK Isbister","year":"2005","unstructured":"Isbister GK, Balit CR, Kilham HA (2005) Antipsychotic poisoning in young children. A systematic review. Drug Saf 28(11):1029\u20131044","journal-title":"Drug Saf"},{"issue":"2","key":"35_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/01.mop.0000151714.87702.a9","volume":"17","author":"D DuBoise","year":"2005","unstructured":"DuBoise D (2005) Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 17(2):227\u2013233","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"35_CR14","first-page":"726","volume":"42","author":"AL Lofton","year":"2004","unstructured":"Lofton AL, Klein-Schwartz W, Spiller HA et al (2004) Prospective multi-center study of ziprasidone exposures [abstract]. J Toxicol Clin Toxicol 42(5):726","journal-title":"J Toxicol Clin Toxicol"},{"issue":"4","key":"35_CR15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/0960327108091170","volume":"27","author":"MB Forrester","year":"2008","unstructured":"Forrester MB (2008) Pattern of ziprasidone exposures reported to Texas poison centers, 2001\u20132005. Human Exp Toxicol 27(4):355\u2013361","journal-title":"Human Exp Toxicol"},{"key":"35_CR16","unstructured":"Geodon [package insert] (2007). Pfizer, New York"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-010-0035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13181-010-0035-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-010-0035-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T13:23:09Z","timestamp":1559568189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13181-010-0035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1007\/s13181-010-0035-4","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}